tiprankstipranks
Trending News
More News >
Iridex (IRIX)
:IRIX
US Market

Iridex (IRIX) Earnings Dates, Call Summary & Reports

Compare
126 Followers

Earnings Data

Report Date
May 08, 2025
TBA Not Confirmed
Period Ending
2025 (Q1)
Consensus EPS Forecast
Last Year’s EPS
-0.18
Same Quarter Last Year
Based on 0 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Mar 27, 2025
|
% Change Since: 12.50%
|
Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for IRIDEX with significant achievements in cost reduction and strategic investment, leading to financial stabilization and revenue growth. However, challenges remain, particularly in the retina product segment and the overall net loss, though the financial performance has improved from the previous year.
Company Guidance
During the fourth quarter of 2024, IRIDEX implemented several strategic initiatives aimed at enhancing business performance for 2025. A key focus was the successful completion of a cost-reduction program, which aligned expenses with revenue projections, contributing to a positive adjusted EBITDA of $0.4 million, a notable improvement from a negative $2.0 million in the prior year. Revenue for Q4 2024 increased to $12.7 million, up from $12.5 million in the same period of the previous year, with a gross profit of $5.6 million, reflecting a 44.0% gross margin. The Cyclo G6 glaucoma product line showed promising growth, generating $3.3 million in revenue and selling 13,300 probes, compared to 12,700 the previous year. Additionally, a strategic investment by Novel Innovations provided $10 million, with an option for an additional $10 million, strengthening the balance sheet and positioning IRIDEX for future growth. The company plans to pre-announce its Q1 2025 results to address a prolonged insider trading window closure and to highlight the perceived undervaluation of its stock, particularly in light of Novel's investment at a $2 per share valuation.
Successful Cost Reduction Program
The company successfully implemented a cost-reduction program, completed in Q4 2024, which stabilized the business and positioned it for positive cash flow from operations.
Strategic Investment by Novel Innovations
IRIDEX received a strategic investment from Novel Innovations, strengthening the balance sheet with $10 million and an option for an additional $10 million. The investment was made at a significant premium, reflecting the strategic nature and potential value of IRIDEX.
Revenue Growth and Improved Financial Performance
IRIDEX reported year-over-year revenue growth in Q4 2024, with revenue increasing to $12.7 million, up from $12.5 million in the prior year. The gross margin improved to 44.0% from 39.2% in the previous year, and the company achieved positive adjusted EBITDA for the first time in recent history.
Increased Sales of Cyclo G6 Glaucoma Products
Sales of the Cyclo G6 glaucoma product family increased by 9%, with 13,300 probes sold compared to 12,700 in the prior year, and 47 laser systems sold compared to 35 in the same quarter of the prior year.
---

Iridex (IRIX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

IRIX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 08, 20252025 (Q1)
- / -
Mar 27, 20252024 (Q4)
- / -0.05
-0.1872.22% (+0.13)
Nov 12, 20242024 (Q3)
-0.09 / -0.12
-0.11-9.09% (>-0.01)
Aug 08, 20242024 (Q2)
-0.12 / -0.16
-0.175.88% (+0.01)
May 14, 20242024 (Q1)
-0.12 / -0.21
-0.13-61.54% (-0.08)
Mar 26, 20242023 (Q4)
-0.05 / -0.18
-0.07-157.14% (-0.11)
Nov 14, 20232023 (Q3)
-0.13 / -0.11
-0.110.00% (0.00)
Aug 10, 20232023 (Q2)
-0.11 / -0.17
-0.14-21.43% (-0.03)
May 11, 20232023 (Q1)
-0.12 / -0.13
-0.1513.33% (+0.02)
Mar 09, 20232022 (Q4)
-0.11 / -0.07
-0.1553.33% (+0.08)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

IRIX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 27, 2025$0.88$1.00+13.64%
Nov 12, 2024$1.41$1.89+34.04%
Aug 08, 2024$1.87$1.86-0.53%
May 14, 2024$3.08$2.65-13.96%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Iridex (IRIX) report earnings?
Iridex (IRIX) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
    What is Iridex (IRIX) earnings time?
    Iridex (IRIX) earnings time is at May 08, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is IRIX EPS forecast?
          Currently, no data Available
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis